Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis: primary endpoint results, effect estimate with…
- Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01842646).
- Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG): Complete Statistical AnalysisIndependent statistical analysis of Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01822691).
- Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02024555).
- Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176605).
- Phase II Neoadjuvant in Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Neoadjuvant in Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756470).
- Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): Complete Statistical AnalysisIndependent statistical analysis of Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00379197).
- Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Pharmacokinetics Study of CAM2038: Complete Statistical AnalysisIndependent statistical analysis of Phase II Pharmacokinetics Study of CAM2038: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02710526).
- Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: primary endpoint results, effect estimate…
- Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Alternating Sunitinib and Temsirolimus: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Alternating Sunitinib and Temsirolimus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01517243).
- Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Doxorubicin and Avastin® in Sarcoma.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Doxorubicin and Avastin® in Sarcoma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00755261).
- Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: primary endpoint results,…
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00299988).
- Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval,…
- Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes: primary endpoint results, effect estimate with confidence interval,…
- Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L): Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol…
- Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00434109).
- Phase II Study of TAK228 in Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAK228 in Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02727777).
- Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00824161).
- Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy: primary endpoint results,…
- Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.: primary endpoint results, effect estimate with…
- Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…